Clinical Pharmacology & Toxicology Pearl of the Week — Unauthorized Injectable Peptides

Summary

This is a Clinical Pharmacology & Toxicology “Pearl of the Week” educational bulletin from the Alberta Health Services Clinical Pharmacology service (University of Calgary Cumming School of Medicine, reviewed 2026-04-20). It summarizes four poison-centre case reports of harm from unauthorized injectable peptides (a 66-fold GHK-Cu overdose, an acute CJC-1295 reaction, a peptide-polypharmacy inflammatory response, and an adolescent acute kidney injury / hypoglycaemia case) and reviews the category-level safety problem. The Heavy Metal Index relevance is contained in two general claims drawn from prior literature: that “some [unauthorized injectable peptides] contain toxic contaminants (e.g., arsenic, lead) or undeclared drugs,” and that “falsified peptides have been found to contain arsenic (up to 10× ICH limits), lead, endotoxins, and incorrect or absent active ingredients.” Both claims are tertiary — they cite Janvier et al. 2018 and Vanhee et al. 2015 rather than reporting original measurements — but the bulletin establishes that heavy-metal contamination of unauthorized injectable peptides is now part of formal clinician-facing toxicology guidance from a Canadian poison-control programme. It also documents Health Canada enforcement actions against named vendors of unauthorized injectable peptides (a regulatory-event context Exception 1).

Key numbers

This bulletin does not present original elemental-impurity measurements. Two quantitative HM-relevant claims are quoted from the cited literature:

Clinical case detail (not HM-relevant but recorded for context):

• Case 1: 50-year-old female; 132 mg subcutaneous GHK-Cu (66-fold dosing error); asymptomatic; outpatient follow-up.
• Case 2: adult male; 300 µg subcutaneous CJC-1295; immediate diarrhoea and difficulty swallowing saliva; resolved spontaneously.
• Case 3: adult male; ~50 mg combined Alpha-1, 5-amino-1-methylquinolinium, and tesamorelin (10-fold dosing error); CRP 151 mg/L, WBC 24.6 × 10⁹/L; supportive care, discharged.
• Case 4: 17-year-old male; stacked hCG, anastrozole, IGF-1 LR3 and CJC-1295 over five days; acute kidney injury and metabolic alkalosis on initial presentation; severe hypoglycaemia at re-presentation three days after peptide cessation; toxicologist raised undisclosed exogenous insulin as the likely explanation.

Evidence Fitness

Methods (brief)

Educational clinical bulletin; not an analytical study. Sources of information cited in the references list include three Talanta / JAMA studies on falsified-peptide impurity profiling and labelling (Janvier 2018, Vanhee 2015, Van Wagoner 2017), FDA product labels for approved peptide therapeutics (EGRIFTA SV, Increlex, Zycubo), preclinical and clinical pharmacology references for individual peptides (Teichman 2006 for CJC-1295 pharmacokinetics, Tomas 1997 and Kerr 1993 for IGF-1, Xu 2020 for BPC-157), a published case of fasciotomy-requiring compartment syndrome after peptide cocktail injection (Lamour 2024), and Canadian regulatory and pricing references. No original chemical analysis was performed for this bulletin.

Implications

• Adds Canadian provincial toxicology-service framing (Alberta Health Services PADIS, CPSA Messenger guidance) to the unauthorized-injectable-peptide contamination picture relevant to Research Chemicals, Peptides & SARMs and Injectable peptide hormones (GLP-1 analogs, GH secretagogues, synthetic peptides).
• Documents named Health Canada enforcement actions against Prime Research (Sherbrooke, QC) and Canada Peptide, supporting the regulatory-context entry for unauthorized injectable peptides as a category subject to active agency surveillance (Part 12 Exception 1 — public-record regulatory event).
• Provides no new occurrence data; for arsenic/lead values in this category use Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market as the primary occurrence source (speciation-confirmed inorganic arsenic at 1660–12,890 ppb in 6/27 falsified peptide preparations).

Related evidence

• Arsenic
• Lead

Update history

The five most recent substantive edits to this page, classified major (evidence or structure moved), correction (a published value or statement was wrong and has been fixed), or minor (narrative rewritten without changing the underlying evidence). Each description is derived from what the edit did to this page; the linked commit is the authoritative record, routine regeneration passes are excluded, and the full version history lives in git.